Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Possibilities of immunotherapy and gene therapy for malignant melanoma.

Crowley NJ, Seigler HF.

Semin Surg Oncol. 1993 May-Jun;9(3):273-8. Review.

PMID:
8516616
2.

[A malignus melanoma immunterápiájának lehetoségei].

Ladányi A.

Magy Onkol. 2003;47(1):113-7. Epub 2003 Apr 18. Review. Hungarian.

3.

Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.

Willemsen R, Ronteltap C, Heuveling M, Debets R, Bolhuis R.

Gene Ther. 2005 Jan;12(2):140-6.

PMID:
15496961
4.

Immunotherapy for melanoma.

Komenaka I, Hoerig H, Kaufman HL.

Clin Dermatol. 2004 May-Jun;22(3):251-65. Review.

PMID:
15262312
5.

Immunological gene therapy approaches for malignant melanoma. 1. Tumor-immunological background.

Bonnekoh B, Bickenbach JR, Roop DR.

Skin Pharmacol. 1997;10(2):49-62. Review.

PMID:
9257373
6.

[Possibilities of immunotherapy in malignant melanoma].

Lewis MG.

Hautarzt. 1978 Dec;29(12):619-24. Review. German.

PMID:
363650
7.

Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.

Andersen MH, Gehl J, Reker S, Pedersen LØ, Becker JC, Geertsen P, thor Straten P.

Semin Cancer Biol. 2003 Dec;13(6):449-59. Review.

PMID:
15001164
8.

[Immunotherapeutic possibilities for treatment of malignant melanomas].

Kokoschka EM.

Hautarzt. 1979 Dec;30(12):656-61. German.

PMID:
317654
9.

The development of gene therapy for the treatment of cancer.

Rosenberg SA, Anderson WF, Blaese M, Hwu P, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Ettinghausen SE, et al.

Ann Surg. 1993 Oct;218(4):455-63; discussion 463-4.

10.

Gene-based therapy of malignant melanoma.

Schadendorf D.

Semin Oncol. 2002 Oct;29(5):503-12. Review.

PMID:
12407515
11.

Update on immunotherapy for melanoma.

Ribas A.

J Natl Compr Canc Netw. 2006 Aug;4(7):687-94. Review.

PMID:
16884670
12.

Biologic therapy of melanoma with cytokines and lymphocytes.

Bear HD, Hamad GG, Kostuchenko PJ.

Semin Surg Oncol. 1996 Nov-Dec;12(6):436-45. Review. Erratum in: Semin Surg Oncol 1997 Nov-Dec;13(6):465.

PMID:
8914208
13.

[Tumor rejection antigen and cancer immunotherapy].

Matsutake T, Nakayama E.

Gan To Kagaku Ryoho. 1995 Nov;22(13):1871-7. Review. Japanese.

PMID:
7487115
14.

[Strategies for gene therapy of melanoma].

Dummer R, Davis-Daneshfar A, Döhring C, Döbbeling U, Burg G.

Hautarzt. 1995 May;46(5):305-8. Review. German.

PMID:
7607892
15.

Melanoma-associated tumor antigens and their clinical relevance to immunotherapy.

Gattoni-Celli S, Cole DJ.

Semin Oncol. 1996 Dec;23(6):754-8. Review.

PMID:
8970598
16.

[Development in the immunotherapy of malignant melanoma].

Tritsch H.

Hautarzt. 1976 Jan;27(1):1-7. Review. German.

PMID:
767300
17.

Immunotherapy, including gene therapy, for metastatic melanoma.

O'Rourke MG, Schmidt CW, O'Rourke TR, Ellem KA.

Aust N Z J Surg. 1997 Dec;67(12):834-41. Review.

PMID:
9451336
18.

Immunological gene therapy approaches for malignant melanoma. 2. Preclinical studies and clinical strategies.

Bonnekoh B, Bickenbach JR, Roop DR.

Skin Pharmacol. 1997;10(3):105-25. Review.

PMID:
9287392
19.

Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.

Liu Y, Saxena A, Zheng C, Carlsen S, Xiang J.

J Gene Med. 2004 Aug;6(8):857-68.

PMID:
15293344
20.

Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.

Meijer SL, Dols A, Urba WJ, Hu HM, Smith II JW, Vetto J, Wood W, Doran T, Chu Y, Sayaharuban P, Alvord WG, Fox BA.

J Immunother. 2002 Jul-Aug;25(4):359-72.

PMID:
12142559

Supplemental Content

Support Center